Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol.
van der Ploeg P, Hendrikse CS, Thijs AM, Westgeest HM, Smedts HP, Vos MC, Jalving M, Lok CA, Boere IA, van Ham MA, Ottevanger PB, Westermann AM, Mom CH, Lalisang RI, Lambrechts S, Bekkers RL, Piek JM. van der Ploeg P, et al. Among authors: westermann am. Heliyon. 2023 Dec 1;10(1):e23170. doi: 10.1016/j.heliyon.2023.e23170. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38187310 Free PMC article.
Immunotherapy for Gestational Trophoblastic Neoplasia: A New Paradigm.
Baas IO, Westermann AM, You B, Bolze PA, Seckl M, Ghorani E. Baas IO, et al. Among authors: westermann am. Gynecol Obstet Invest. 2024;89(3):230-238. doi: 10.1159/000533972. Epub 2023 Sep 13. Gynecol Obstet Invest. 2024. PMID: 37703867 Free PMC article. Review.
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A; INOVATYON study group. Colombo N, et al. Br J Cancer. 2023 Apr;128(8):1503-1513. doi: 10.1038/s41416-022-02108-7. Epub 2023 Feb 9. Br J Cancer. 2023. PMID: 36759720 Free PMC article. Clinical Trial.
Is suffering a sufficient legitimation for UTx?
Bozzaro C, Weismann M, Westermann AM, Alkatout I. Bozzaro C, et al. Among authors: westermann am. Bioethics. 2023 May;37(4):350-358. doi: 10.1111/bioe.13135. Epub 2023 Feb 9. Bioethics. 2023. PMID: 36758127
RANKL inhibition for giant cell lesions of the jaw: A retrospective cohort analysis.
Schreuder WH, Lipplaa A, Cleven AHG, van den Berg H, Bisschop PH, de Jongh RT, Witjes MJH, Kessler PAWH, Merkx MAW, Edelenbos E, Klop C, Schreurs R, Westermann AM, Tromp JM, Levenga H, Gelderblom H, de Lange J. Schreuder WH, et al. Among authors: westermann am. Eur J Cancer. 2022 Nov;175:263-273. doi: 10.1016/j.ejca.2022.08.011. Epub 2022 Sep 26. Eur J Cancer. 2022. PMID: 36174298 Free article.
The pelvitrainer for training in laparoscopic surgery - A prospective, multicenter, interdisciplinary study: Experimental research.
Ackermann J, Pahls J, Baumann J, Spüntrup C, Holthaus B, Noé G, Anapolski M, Meinhold-Heerlein I, Laganà AS, Peters G, Pape J, Willer D, Westermann AM, Günther V, Maass N, Mettler L, Alkatout I. Ackermann J, et al. Among authors: westermann am. Int J Surg. 2022 May;101:106604. doi: 10.1016/j.ijsu.2022.106604. Epub 2022 Apr 7. Int J Surg. 2022. PMID: 35398529 Free article.
Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).
Post CCB, Westermann AM, Boere IA, Witteveen PO, Ottevanger PB, Sonke GS, Lalisang RI, Putter H, Meershoek-Klein Kranenbarg E, Braak JPBM, Creutzberg CL, Bosse T, Kroep JR. Post CCB, et al. Among authors: westermann am. Gynecol Oncol. 2022 May;165(2):223-229. doi: 10.1016/j.ygyno.2022.02.025. Epub 2022 Mar 11. Gynecol Oncol. 2022. PMID: 35287967 Free article. Clinical Trial.
62 results